top of page
AI pixabay huge.jpg

Huma receives US FDA Class II clearance for SaMD platform

Huma Therapeutics has received US Food and Drug Administration (FDA) Class II clearance for its disease-agnostic Software-as-a-Medical-Device (SaMD) platform, enabling companies to launch their own algorithm innovations more quickly to the platform and allowing AI algorithms for disease prognostication and recommendations for treatment.


Exclusive: Huma receives US FDA Class II clearance for SaMD platform (digitalhealth.net)




bottom of page